News

JPEO-CBRND Announces Openings for Acquisition Soldiers
October 17, 2022 — For Army acquisition officers with the rank of captain through colonel set to have a permanent change of station in summer 2023, the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) has announced four opportunities to serve at JPEO-CBRND during this year’s Assignment Interactive Module version 2, or “AIM 2.”... MORE

Soldiers wear the M53A1 respirator with the ST-54 Self Contained Breathing Apparatus (SCBA) and Combination System Powered Air Purifying Respirator (CS-PAPR).

AFLCMC, JPEO collaborate to set up SAL capabilities demo during Toxic Pineapple II
October 11, 2022 — The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense recently collaborated alongside the Air Force Life Cycle Management Center Air Force CBRN Defense Systems Branch and the 15th Wing to deliver a standalone large shelter during exercise Toxic Pineapple II at Hickam Air Force Base, Aug. 29 to Sept. 1... MORE

Agencies collaborate to set up capabilities demo during Toxic Pineapple II

Beacon of Light: NSWC Philadelphia Division Employee Awarded Armed Forces Civilian Medal for Pandemic Support
September 28, 2022 — Naval Surface Warfare Center, Philadelphia Division employee Andrew C. Lucas was awarded the Armed Forces Civilian Service Medal (AFCSM) for participating on the Joint Assisted Acquisition (JA2) program that provided the acquisition and technical expertise needed to transition and accelerate the U.S. Government’s ongoing COVID-19 response and pandemic preparedness. The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense’s Joint Assisted Acquisition (JPEO-CBRND) JA2 team was established to serve as part of the U.S. government response, working at the forefront of ensuring that global health goals were supported, and that the international community was well-equipped to combat this pandemic... MORE

Naval Surface Warfare Center, Philadelphia Division employee Andrew C. Lucas was awarded the Armed Forces Civilian Service Medal (AFCSM) for participating on the Joint Assisted Acquisition (JA2) program

Joint Project Manager for CBRN Medical National Stock Number Sponsorship Supports Access to Critical Medical Countermeasures
September 26, 2022 — Since the beginning of the current global pandemic, the JPM CBRN Medical has played a critical role in facilitating the assignment of NSNs to relevant medical countermeasures (MCMs), resulting in increased access to protective medicines for our nation’s service members. The JPM CBRN Medical’s focus has been to identify products with supporting data from the COVID response or other approved products, which demonstrate how the product can be used as a MCM against CBRN threats... MORE

DOD Awards Follow-on Production Agreement for Rapid Opioid Countermeasure System Program Naloxone Autoinjectors
September 20, 2022 — JPM CBRN Medical awarded a follow-on Other Transaction Authority (OTA) for Production agreement to kaléo, Inc. The contract follows a previous OTA awarded to kaléo in 2019 to develop the 10mg NAI in collaboration with the JPM CBRN Medical and the Chemical and Biological Defense Program (CBDP). Under this follow-on OTA, awarded through the Army Contracting Command, kaléo will manufacture and deliver 10mg naloxone autoinjectors (NAI) as a residual capability to the DoD’s Special User Groups, as well as an emergency stockpile no later than September 2022. ... MORE

While wearing MOPP Level 4 gear a test player prepares to use a ROCS auto-injector on a simulated causality.

DOD Initiates Phase II Clinical Trial in Support of Vaccine Acceleration Program
September 12, 2022 — Dynavax, in collaboration with the JPM CBRN Medical, began a Phase II clinical trial using the JPM CBRN Medical’s Recombinant Plague (rF1V) vaccine, with Dynavax’s biological response modifier (BRM) cytosine phosphoguanine (CpG) 1018®, to help improve the vaccine’s onset of protection and efficacy level. This clinical trial will serve as a launching point to evaluate new vaccine enhancements that will help ensure vaccines are operationally relevant to the warfighter. The DOD’s Chemical and Biological Defense Program supported this effort... MORE

Rapid Opioid Countermeasure System Product Team Wins 2022 Military Health System Research Symposium Award for Outstanding Program Management Team
September 12, 2022 — JPM CBRN Medical Rapid Opioid Countermeasure System (ROCS) product team was selected to receive the 2022 MHSRS award for Outstanding Program Management (Team). This award recognizes outstanding medical product program management, highlighting team accomplishments that further mature medical research and development or commercial efforts. The ROCS team was recognized for addressing and minimizing the ROCS program’s developmental risks, managing cost, schedule, and performance, and adhering to all applicable regulatory requirements... MORE

Rapid Opioid Countermeasure System (ROCS) product team receives the 2022 MHSRS award for Outstanding Program Management (Team)

DoD Awards Synthetic Human Antibody Prototype Agreement to Treat High-Priority Toxins and Pathogens
August 24, 2022 — JPM CBRN Medical awarded a prototype agreement through Army Contracting Command with GigaGen, Inc., a subsidiary of Grifols. This agreement will evaluate if GigaGen’s novel platform capabilities can rapidly create a fully-synthetic human antibody product to protect against botulinum neurotoxins (BoNT) A and B. The prototype agreement can support follow-on testing against other DoD-priority toxins and pathogens, as well as advanced development activities including manufacturing and clinical testing to demonstrate improved potency and military utility. ... MORE

FDA Approves New Drug Application for the DoD’s Advanced Anticonvulsant System Program
August 24, 2022 — JPM CBRN Medical received notice of U.S. Food and Drug Administration (FDA) approval of Rafa's midazolam injection autoinjector New Drug Application. The Defense Department (DoD) developed the product with Rafa, via JPM CBRN Medical’s Advanced Anticonvulsant System (AAS) program team. The DoD’s Chemical and Biological Defense Program supported this effort... MORE

Senior U.S. Army civilian retires from Department of Defense's premier all hazards command
August 19, 2022 — The senior Army civilian at the Department of Defense’s premier multifunctional all hazards command completed more than 43 years of uniformed and civilian service, Aug. 18. Dr. Mark W. Fishback retired from the 20th Chemical, Biological, Radiological, Nuclear, Explosives (CBRNE) Command during a widely attended ceremony on Aberdeen Proving Ground, Maryland... MORE

Dr. Mark W. Fishback retired from the 20th Chemical, Biological, Radiological, Nuclear, Explosives (CBRNE) Command as the deputy to the commanding general and senior U.S. Army civilian

News Search

News Archive - Search by Year and Month

April 2024 (1)
March 2024 (3)
February 2024 (3)
January 2024 (2)
December 2023 (2)
November 2023 (2)
October 2023 (5)
September 2023 (6)
August 2023 (8)
July 2023 (2)
June 2023 (2)
May 2023 (3)
April 2023 (2)
March 2023 (1)
February 2023 (1)
January 2023 (1)
December 2022 (4)
November 2022 (1)
October 2022 (3)
September 2022 (5)
August 2022 (3)
July 2022 (3)
June 2022 (1)
May 2022 (1)
March 2022 (2)
February 2022 (2)
January 2022 (5)
December 2021 (1)
November 2021 (6)
October 2021 (2)
September 2021 (1)
July 2021 (1)
June 2021 (1)
May 2021 (8)
April 2021 (6)
March 2021 (2)
February 2021 (5)
January 2021 (4)
December 2020 (3)
November 2020 (1)
August 2020 (1)
July 2020 (3)
May 2020 (1)
April 2020 (1)
March 2020 (4)
February 2020 (1)
December 2019 (2)
November 2019 (2)
October 2019 (2)
September 2019 (2)
March 2019 (1)
January 2019 (2)
December 2018 (1)
October 2018 (1)
July 2018 (1)
April 2018 (1)
February 2018 (1)
December 2017 (1)
November 2017 (2)
September 2017 (1)
June 2017 (2)
January 2017 (3)
December 2016 (1)

JPEO-CBRND Press Kit

Download our press kit, which includes helpful documents to better understand our work, such as – Command Brief, Chemical Biological Defense Program's Enterprise strategy, the JPEO-CBRND's Capabilities Catalog, Leadership Biographies, COVID-19 fact sheets, and contracting overview documents.

JPEO-CBRND Public Affairs Office

The JPEO-CBRND Public Affairs Office coordinates and responds to all public affairs and media relations needs on behalf of the JPEO-CBRND. To request a speaker, subject matter expert, or for other interview or request for comment please email our Public Affairs Office email below.